February 14, 2017: Sell Cynosure for a huge 36.5% win in 28 days. Cynosure will be acquired by Hologic for $66 per share. Congratulations if you were able to make money on this trade.
February 7, 2017: Cynosure reports Q4 EPS of $0.44 versus the $0.41 estimate. Revenue also beat coming in at $122 million versus the $120 million estimate.
The CEO Michael Davin said, “Demand for aesthetic procedures in North America was our largest growth driver over the course of 2016, led by the full launch of our SculpSure platform in the first quarter. Our international business gained momentum in the second half of 2016, reflecting our focus on securing additional regulatory clearances such as the third quarter 2016 marketing approval of SculpSure in Korea and the China Food and Drug Administration’s clearance of the Icon™ Aesthetic System in November.”
January 23, 2017: Stifel analyst says Cynosure could be worth up to $70 per share in a takeover scenario.
January 22, 2017: The mainstream financial press is reporting that Cynosure is exploring strategic options including a possible sale in a deal said to be worth up to $1 billion.
January 3, 2017: Cynosure stock exploded higher today. Stocks usually don’t move like this without a big news release coming.
Cynosure Stock Chart
Cynosure develops, manufactures, and markets aesthetic treatment systems that enable plastic surgeons, dermatologists and other medical practitioners to perform non-invasive and minimally invasive procedures to remove hair, treat vascular and benign pigmented lesions, remove multi-colored tattoos, revitalize the skin, liquefy and remove unwanted fat through laser lipolysis, reduce cellulite, clear nails infected by toe fungus, ablate sweat glands and improve vaginal health.